Inflammation

Ranbaxy's Drug Discovery Team Achieves Significant Milestone In Gsk Research Collaboration

Published in Drug Law Weekly, April 17th, 2007

Ranbaxy Laboratories Limited (Ranbaxy) announced today that its New Drug Discovery Research (NDDR) team has achieved a significant milestone in its collaboration with GSK. The Steering Committee, consisting of senior members from GSKs Center of Excellence for External Drug Discovery (CEEDD) and Ranbaxy, has approved the candidate selection of a compound for Respiratory Inflammation.

As per the recently signed multi-year agreement, Ranbaxy will be able to progress and further profile this drug candidate through pre-clinical studies needed to support an Investigational New Drug (IND) application. Ranbaxy will also be responsible for conducting Phase I and Phase II...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2007-04-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry